Global Health Services to Enjoy Cost Savings from Expanded CE Mark for the Geko Blood Circulation Device
HIGH WYCOMBE, England, January 29, 2013 /PRNewswire/ –
European regulators have approved CE Mark extensions for the transformational geko
[http://gekodevices.com/en-us ] device, designed to increase blood circulation for a range
of circulatory disorders.
Bosses at Firstkind Medical [http://gekodevices.com/en-us/contact/firstkind ], a
wholly owned subsidiary of Sky Medical Technology [http://www.skymedtech.com ], say the
decision will allow the geko(TM) device to move beyond its initial use for the prevention
of deep vein thrombosis (DVT) and reduce global healthcare costs in the process.
Clinicians currently use the device as an alternative to compression stockings, IPC
devices or anticoagulants for DVT prophylaxis. The expanded approvals will allow
clinicians to use the geko to promote wound healing, prevention and treat oedema, venous
insufficiency and ischemia, where the veins struggle to send blood back from the legs to
“This new approval will allow us to extend the proven circulation benefits of geko
device to a number of key clinical indications. It’s a clever device, simple to use and
well tolerated by patients, so we’re pleased that we’ll be able to help them in other
ways,” said Ross.
The wristwatch-size device fits to the back of the knee and delivers painless
electrical impulses, via the common peroneal nerve, to gently activate the muscle pumps in
the lower leg. The mechanism of action returns blood to the heart at a rate shown to be up
to 70% of walking, without the user having to move or exert energy.
“It’s this simplicity and accelerated patient mobility that differentiates the geko
device” says Ross. “Now we can expect better patient outcomes across a range of
indications, reduced length of hospital stay and substantial cost savings for health
Issued on behalf of Firstkind Medical Ltd by Paver Smith [http://www.paversmith.co.uk
Note to editors:
Firstkind Medical Ltd
Firstkind Medical Limited is a wholly owned subsidiary of Sky Medical Technology
[http://www.skymedtech.com ] Limited (“Sky Medical”), a privately-held UK company based in
High Wycombe, Buckinghamshire.
Sky Medical manufacture medical devices using OnPulseTM, Sky Medical’s proprietary
neuromuscular electro-stimulation technology, indicated for increased blood circulation,
for the prevention of venous thrombosis, for the prevention and treatment of oedema, for
promoting wound healing and for the treatment of venous insufficiency and ischemia. The
clinically effective OnPulseTM technology is non-invasive and embedded within the small,
portable, one-size-fits-all gekoTM device, that is easily attached to the back of the
The gekoTM device, incorporating OnPulseTM technology, has received CE Marking and is
approved in Europe, Australia and Canada for increasing blood circulation, for the
prevention of venous thrombosis, for the prevention and treatment of oedema, for promoting
wound healing and for the treatment of venous insufficiency and ischemia. The gekoTM
device and other embodiments of the OnPulseTM technology have not been cleared by the US
FDA and are not available for sale in the USA.
SOURCE Firstkind Medical Ltd